Freshly Printed - allow 7 days lead
Couldn't load pickup availability
Children and Drug Safety
Balancing Risk and Protection in Twentieth-Century America
Cynthia A Connolly (Author)
9780813563886
Hardback, published 11 May 2018
260 pages, 8
22.9 x 15.2 x 1.8 cm, 0.49 kg
Children’s aspirin is a stark example of that. St. Joseph Aspirin for Children was released in 1947. It was orange-colored and orange-flavored and often advertised as “candy aspirin.” And “within a few years of its introduction, the incidence of aspirin poisoning in young children increased dramatically, almost five hundred percent,” writes Cynthia Connolly, a professor of nursing at the University of Pennsylvania who studies the history of pediatric health care. “I, myself, am a former aspirin-poisoned child,” Connolly told me. It happened in 1961 or 1962, when she was 3 or 4 years old, she says. “My parents kept it up high because they knew I loved it. It had a wonderful granular taste; it tastes like a SweeTart. One time when they weren’t looking, I got up there and got the St. Joseph Aspirin for Children, took almost the whole bottle, and then fell off the counter and broke my arm. While still holding the medicine by the way.” Her parents found her when she screamed, and she had to go to the hospital and get her stomach pumped-and her arm set.
The dangers of candy aspirin led to the development of the safety cap, Connolly writes. And the pharmaceutical industry came to realize that it probably wasn’t a great idea to sell medicine as “candy.”
Children’s aspirin is a stark example of that. St. Joseph Aspirin for Children was released in 1947. It was orange-colored and orange-flavored and often advertised as “candy aspirin.” And “within a few years of its introduction, the incidence of aspirin poisoning in young children increased dramatically, almost five hundred percent,” writes Cynthia Connolly, a professor of nursing at the University of Pennsylvania who studies the history of pediatric health care. “I, myself, am a former aspirin-poisoned child,” Connolly told me. It happened in 1961 or 1962, when she was 3 or 4 years old, she says. “My parents kept it up high because they knew I loved it. It had a wonderful granular taste; it tastes like a SweeTart. One time when they weren’t looking, I got up there and got the St. Joseph Aspirin for Children, took almost the whole bottle, and then fell off the counter and broke my arm. While still holding the medicine by the way.” Her parents found her when she screamed, and she had to go to the hospital and get her stomach pumped-and her arm set.
The dangers of candy aspirin led to the development of the safety cap, Connolly writes. And the pharmaceutical industry came to realize that it probably wasn’t a great idea to sell medicine as “candy.”
Children and Drug Safety traces the development, use, and marketing of drugs for children in the twentieth century, a history that sits at the interface of the state, business, health care providers, parents, and children. This book illuminates the historical dimension of a clinical and policy issue with great contemporary significance-many of the drugs administered to children today have never been tested for safety and efficacy in the pediatric population.
Each chapter of Children and Drug Safety engages with major turning points in pediatric drug development; themes of children’s risk, rights, protection and the evolving context of childhood; child-rearing; and family life in ways freighted with nuances of race, class, and gender. Cynthia A. Connolly charts the numerous attempts by Congress, the Food and Drug Administration, the American Academy of Pediatrics, and leading pediatric pharmacologists, scientists, clinicians, and parents to address a situation that all found untenable.
Open access edition funded by the National Endowment for the Humanities.
The text of this book is licensed under a Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Baby Killers”
to Baby Savers, 1906–
1933
2. New Drugs, Old Problems in Pediatrics: From Therapeutic Nihilism to the Antibiotic Era, 1933–
1945
3. The Child as Drug Development Problem and Business Opportunity in a New Era, 1945-1961
4. The Growth and Development of the Therapeutic Orphan: 1961-1979
5. A “
Big Business Built for Little Customers:”
Candy Aspirin, Children, and Poisoning, 1947–
1976
6. Children and Psychopharmacology in Postwar America
7. Pediatric Drug Development and Policy after 1979
Appendix
Acknowledgements
Notes
Index